Titan Pharmaceuticals (NASDAQ:TTNP) entered into an asset purchase agreement with Fedson for the sale of certain ProNeura assets, including Titan’s portfolio of drug addiction products, in addition to other early...
Carmell Therapeutics (NASDAQ:CTCX) signed a definitive agreement and plan of merger with Axoloti Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and...
Humacyte (NASDAQ:HUMA) completed enrollment of its Phase 2/3 vascular trauma trial that is expected to support a BLA filing for Humacyte’s human acellular vessel (HAV) in vascular trauma repair planned for the fourth...
Closely-held Symetryx increased its non-binding proposal to acquire Check-Cap (NASDAQ:CHEK) to $4.60 a share from $4.35 when it announced its offer on July 18. At last report, Check-Cap had 5.8 million shares...
Enzo Biochem (NYSE:ENZ) closed a transaction to sell certain assets of Enzo’s clinical laboratory division (Enzo Clinical Labs) to Laboratory Corp. of America Holdings (NYSE:LH) for $113.25-million. In accordance with...
IntelGenx (TSX:IGX; OTCQB:IGXT) finalized a research grant agreement with Sweden’s Karolinska University Hospital and that the manufacturing of both active and placebo films are underway for a planned multicentre...
Infinity Pharmaceuticals (NASDAQ:INFI) terminated its merger agreement to merge with MEI Pharma (NASDAQ:MEIP). At a special meeting of MEI stockholders on July 23, MEI did not obtain stockholder approval for the merger...
Axxess, a home healthcare technology provider, acquired Complia Health in move that adds more clients, more talent and even greater engagement with leading care providers among the Axxess family. Complia’s roster of...
Advent Therapeutics received FDA rare pediatric disease designation for its vitamin A metabolic and reparative respiratory drugs for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. BPD is a rare...
Eliem Therapeutics (NASDAQ:ELYM) completed a review of its business, including the status of its programs, resources, and capabilities, and has decided to halt further development of its Kv7 program and to conduct a...
MindBio Therapeutics Corp (CSE:MBIO; Frankfurt:WF6) started pre-screening for participant entry into Phase 2 LSD-microdosing clinical trials. The clinical trials are a world first with approvals for take home use of...
Close-held Neurogene and Neoleukin Therapeutics (NASDAQ:NLTX) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene’s...
A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...
Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Finland for demonstrating “exceptional perseverance and clinical...
Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International...
First Wave BioPharma’s (NASDAQ:FWBI) is unlikely to achieve the primary endpoint based on preliminary results from the Phase 2 SPAN study for the treatment of exocrine pancreatic insufficiency in patients with cystic...
The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...
With sales falling short of expectations, Theratechnologies (TSX:TH; NASDAQ:THTX) is reducing its R&D head count. Second quarter revenue fell 8.9% to $17.5-million (U.S.) from $19.3-million a year ago. “Second...
The FDA granted fast track designation to Synlogic’s (NASDAQ:SYBX) labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac also has received rare...
The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...
MAIA Biotechnology (NYSEA: MAIA) updated preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced...
The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...